TScan Therapeutics, Inc. Balance Sheet
TCRX|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
TScan Therapeutics, Inc. had $229M in total assets and $241M in shareholders' equity as of FY2025. Total debt was $33M against $152M in cash, resulting in a $120M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $152.4M | $178.7M | $133.4M | $120.0M | $161.4M |
| Current Assets | $157.2M | $292.7M | $194.2M | $124.1M | $165.7M |
| PP&E (Net) | $8.7M | $7.2M | $7.7M | $10.1M | $11.8M |
| Total Assets | $228.8M | $371.1M | $272.1M | $199.1M | $188.1M |
| Current Liabilities | $18.7M | $36.0M | $29.8M | $17.3M | $21.3M |
| Total Debt | $32.5M | $32.1M | $26.7M | $29.3M | - |
| Shareholders' Equity | $241.0M | $150.9M | $99.4M | $160.8M | -$42.5M |